Susquehanna International Group
XRTX

Susquehanna International Group’s XORTX Therapeutics XRTX Stock Holding History

Susquehanna International Group’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-53
Closed -$10.1K – 13293
2023
Q1 		$10.1K Buy
+53
New +$13.3K ﹤0.01% 12205
2022
Q2 		– Sell
-72
Closed -$58K – 14086
2022
Q1 		$58K Buy
+72
New +$47.5K ﹤0.01% 12245

Other funds holding XRTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's XRTX Position: Q2 2023 in Review

Susquehanna International Group sold out of XORTX Therapeutics (XRTX) in Q2 2023, closing a stake of 53 shares — an estimated $10.1K sold.

Susquehanna International Group first reported a position in XRTX in Q1 2022 and held it in 2 quarters. The position peaked at $58K in Q1 2022. 3 funds tracked by Wall St. Rank hold XRTX as of Q2 2023.

  • Susquehanna International Group reported no remaining XORTX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 53 XORTX Therapeutics shares in Q2 2023, an estimated $10.1K.
  • Susquehanna International Group first reported a position in XORTX Therapeutics in Q1 2022 and held it in 2 quarters.
  • Susquehanna International Group's XORTX Therapeutics position peaked at $58K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.